Intravenous with intrathecal interferon in subacute sclerosing panencephalitis

Area of Science:

• Neuroscience
• Immunology
• Virology

Background:

• Subacute sclerosing panencephalitis (SSPE) is a rare, progressive neurological complication of measles infection.
• Previous studies on interferon treatment for SSPE have yielded variable results globally.
• There is a need to evaluate novel therapeutic strategies for SSPE.

Purpose of the Study:

• To assess the efficacy and safety of combined intravenous and intrathecal interferon ALFA-2a in treating subacute sclerosing panencephalitis (SSPE).

Main Methods:

• Twelve patients diagnosed with SSPE underwent treatment with recombinant interferon ALFA-2a via both intravenous and intrathecal routes.
• Diagnosis was confirmed using clinical evaluation, EEG, CT scans, and CSF analysis for measles IgG antibodies.
• Treatment dosages varied, and patient outcomes were monitored using the Neurological disability index.

Main Results:

• Clinical improvement was observed in three out of twelve patients, with one maintaining improvement long-term.
• Two patients relapsed after therapy cessation.
• No significant changes were noted in EEG, and a decrease in CSF anti-measles antibody titers correlated with improvement in only two patients. Two patients developed iatrogenic meningitis, which was successfully treated. Three patients died during the study.
• Overall, the combined interferon approach showed limited efficacy in SSPE.

Conclusions:

• Combined intravenous and intrathecal interferon ALFA-2a therapy is not a promising treatment for subacute sclerosing panencephalitis (SSPE).
• Further research into more effective therapeutic interventions for SSPE is warranted.